3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
60
Burkitt Lymphoma
10
Recurrence
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Immunoglobulin Light-chain Amyloidosis
2
Down Syndrome
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Plasmacytoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Interventions
Prednisone
5
Docetaxel
4
niraparib
2
Abiraterone Acetate
2
olaparib
1
ibrutinib
1
fludrocortisone acetate
1
enzalutamide
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pluvicto
1
Pioglitazone
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
30 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled